van Leeuwen P - Search Results

1

Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting.

Aluwini SS, Mehra N, Lolkema MP, Oprea-Lager DE, Yakar D, Stoevelaar H, van der Poel H; Dutch Oligometastatic Prostate Cancer Working Group; Busstra M, de Jong IJ, de Reijke T, de Vries K, Heijmink S, Jenster G, Klaver S, Kneppers J, Lavalaye J, Leyten G, Moonen L, Nagaraj J, Noordzij W, Osanto S, Oving I, Schaake E, Scheenen T, Schoots I, Sedelaar M, Somford D, van den Berkmortel F, van der Hulle T, van der Voort van Zyp J, van Leeuwen P, van Moorselaar J, van Oort I, Vogel W, Westgeest H. Aluwini SS, et al. Among authors: van moorselaar j, van oort i, van der poel h, van den berkmortel f, van der voort van zyp j, van der hulle t, van leeuwen p. Eur Urol Oncol. 2020 Apr;3(2):231-238. doi: 10.1016/j.euo.2019.07.010. Epub 2019 Aug 8. Eur Urol Oncol. 2020. PMID: 31401014

2

Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer.

Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, Schröder FH, van der Kwast TH. Wolters T, et al. Eur Urol. 2010 May;57(5):821-9. doi: 10.1016/j.eururo.2009.07.027. Epub 2009 Jul 29. Eur Urol. 2010. PMID: 19664875

3

Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies.

Schröder FH, van den Bergh RC, Wolters T, van Leeuwen PJ, Bangma CH, van der Kwast TH, Roobol MJ. Schröder FH, et al. Eur Urol. 2010 Feb;57(2):256-66. doi: 10.1016/j.eururo.2009.10.031. Epub 2009 Nov 6. Eur Urol. 2010. PMID: 19913350

4

Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test.

Roobol MJ, Schröder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, Hessels D. Roobol MJ, et al. Among authors: van den bergh rc, van leenders gj, van leeuwen p. Eur Urol. 2010 Oct;58(4):475-81. doi: 10.1016/j.eururo.2010.06.039. Epub 2010 Jul 9. Eur Urol. 2010. PMID: 20637539 Clinical Trial.

5

Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).

Roobol MJ, Schröder FH, van Leenders GL, Hessels D, van den Bergh RC, Wolters T, van Leeuwen PJ. Roobol MJ, et al. Eur Urol. 2010 Dec;58(6):893-9. doi: 10.1016/j.eururo.2010.09.030. Epub 2010 Sep 26. Eur Urol. 2010. PMID: 20933321 Clinical Trial.

6

A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.

Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, Schröder FH, van der Kwast TH. Wolters T, et al. J Urol. 2011 Jan;185(1):121-5. doi: 10.1016/j.juro.2010.08.082. Epub 2010 Nov 12. J Urol. 2011. PMID: 21074212

7

Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.

van Leeuwen PJ, Kölble K, Huland H, Hambrock T, Barentsz J, Schröder FH. van Leeuwen PJ, et al. Eur Urol. 2011 Feb;59(2):183-90. doi: 10.1016/j.eururo.2010.09.035. Epub 2010 Dec 4. Eur Urol. 2011. PMID: 21130560 Review.

8

Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam.

Bul M, van Leeuwen PJ, Zhu X, Schröder FH, Roobol MJ. Bul M, et al. Eur Urol. 2011 Apr;59(4):498-505. doi: 10.1016/j.eururo.2011.01.001. Epub 2011 Feb 18. Eur Urol. 2011. PMID: 21334136 Free article. Clinical Trial.

9

Updating the prostate cancer risk indicator for contemporary biopsy schemes.

Bul M, Delongchamps NB, Steyerberg EW, de la Roza G, van Leeuwen PJ, Zhu X, van Vugt HA, Haas GP, Schröder FH, Roobol MJ. Bul M, et al. Among authors: van vugt ha, van leeuwen pj. Can J Urol. 2011 Apr;18(2):5625-9. Can J Urol. 2011. PMID: 21504651

10

Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.

Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ. Zhu X, et al. Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17. Eur Urol. 2011. PMID: 21601352 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

702 results

Search Page